HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

Abstract
Pre-clinical studies in mice and haemophilic dogs have shown that introduction of an adeno-associated viral (AAV) vector encoding blood coagulation factor IX (FIX) into skeletal muscle results in sustained expression of F.IX at levels sufficient to correct the haemophilic phenotype. On the basis of these data and additional pre-clinical studies demonstrating an absence of vector-related toxicity, we initiated a clinical study of intramuscular injection of an AAV vector expressing human F.IX in adults with severe haemophilia B. The study has a dose-escalation design, and all patients have now been enrolled in the initial dose cohort (2 x 10(11) vg/kg). Assessment in the first three patients of safety and gene transfer and expression show no evidence of germline transmission of vector sequences or formation of inhibitory antibodies against F.IX. We found that the vector sequences are present in muscle by PCR and Southern-blot analyses of muscle biopsies and we demonstrated expression of F.IX by immunohistochemistry. We observed modest changes in clinical endpoints including circulating levels of F.IX and frequency of FIX protein infusion. The evidence of gene expression at low doses of vector suggests that dose calculations based on animal data may have overestimated the amount of vector required to achieve therapeutic levels in humans, and that the approach offers the possibility of converting severe haemophilia B to a milder form of the disease.
AuthorsM A Kay, C S Manno, M V Ragni, P J Larson, L B Couto, A McClelland, B Glader, A J Chew, S J Tai, R W Herzog, V Arruda, F Johnson, C Scallan, E Skarsgard, A W Flake, K A High
JournalNature genetics (Nat Genet) Vol. 24 Issue 3 Pg. 257-61 (Mar 2000) ISSN: 1061-4036 [Print] United States
PMID10700178 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Recombinant Fusion Proteins
  • Factor IX
Topics
  • Adult
  • Aged
  • Blood Coagulation Tests
  • Blotting, Southern
  • Dependovirus (genetics)
  • Factor IX (analysis, genetics)
  • Gene Expression
  • Genetic Therapy
  • Genetic Vectors (administration & dosage, genetics, therapeutic use)
  • Hemophilia B (genetics, therapy)
  • Humans
  • Injections, Intramuscular
  • Male
  • Muscle, Skeletal (metabolism, virology)
  • Polymerase Chain Reaction
  • Recombinant Fusion Proteins (analysis, biosynthesis, genetics)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: